AU2014231722B2 - Salts, co-crystals, and polymorphs of an anxiolytic compound - Google Patents

Salts, co-crystals, and polymorphs of an anxiolytic compound Download PDF

Info

Publication number
AU2014231722B2
AU2014231722B2 AU2014231722A AU2014231722A AU2014231722B2 AU 2014231722 B2 AU2014231722 B2 AU 2014231722B2 AU 2014231722 A AU2014231722 A AU 2014231722A AU 2014231722 A AU2014231722 A AU 2014231722A AU 2014231722 B2 AU2014231722 B2 AU 2014231722B2
Authority
AU
Australia
Prior art keywords
compound
peaks
salt
certain embodiments
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014231722A
Other languages
English (en)
Other versions
AU2014231722A1 (en
Inventor
Bernard Luke Flynn
Raymond E. Forslund
Andrew John Harvey
Ahmad Hashash
Rob LIVINGSTON
Dharam Paul
Vasu V. SETHURAMAN
Song Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Ironwood Pharmaceuticals Inc
Original Assignee
Bionomics Ltd
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd, Ironwood Pharmaceuticals Inc filed Critical Bionomics Ltd
Publication of AU2014231722A1 publication Critical patent/AU2014231722A1/en
Application granted granted Critical
Publication of AU2014231722B2 publication Critical patent/AU2014231722B2/en
Priority to AU2017201916A priority Critical patent/AU2017201916B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014231722A 2013-03-15 2014-03-14 Salts, co-crystals, and polymorphs of an anxiolytic compound Active AU2014231722B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017201916A AU2017201916B2 (en) 2013-03-15 2017-03-21 Salts, co-crystals, and polymorphs of an anxiolytic compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798926P 2013-03-15 2013-03-15
US61/798,926 2013-03-15
PCT/AU2014/000272 WO2014138812A1 (en) 2013-03-15 2014-03-14 Salts, co-crystals, and polymorphs of an anxiolytic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201916A Division AU2017201916B2 (en) 2013-03-15 2017-03-21 Salts, co-crystals, and polymorphs of an anxiolytic compound

Publications (2)

Publication Number Publication Date
AU2014231722A1 AU2014231722A1 (en) 2015-09-24
AU2014231722B2 true AU2014231722B2 (en) 2016-12-22

Family

ID=51535621

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014231722A Active AU2014231722B2 (en) 2013-03-15 2014-03-14 Salts, co-crystals, and polymorphs of an anxiolytic compound
AU2017201916A Active AU2017201916B2 (en) 2013-03-15 2017-03-21 Salts, co-crystals, and polymorphs of an anxiolytic compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017201916A Active AU2017201916B2 (en) 2013-03-15 2017-03-21 Salts, co-crystals, and polymorphs of an anxiolytic compound

Country Status (9)

Country Link
US (2) US9745296B2 (https=)
EP (1) EP2970247A4 (https=)
JP (1) JP2016510768A (https=)
CN (1) CN105492440A (https=)
AU (2) AU2014231722B2 (https=)
CA (1) CA2905570A1 (https=)
HK (1) HK1220191A1 (https=)
MX (1) MX2015013059A (https=)
WO (1) WO2014138812A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6688434B2 (en) 2002-02-22 2004-02-10 Ecolab Inc. Conveyor and lubricating apparatus, lubricant dispensing device, and method for applying lubricant to conveyor
CN105541701A (zh) * 2015-12-11 2016-05-04 吉林大学珠海学院 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法
TWI823344B (zh) * 2015-12-15 2023-11-21 以色列商諾威股份有限公司 用於測量圖案化結構之特性的系統
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CA3149182A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder
CN121646412A (zh) * 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535803A1 (en) * 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
NZ576036A (en) * 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
GB0706044D0 (en) * 2007-03-28 2007-05-09 Syngenta Ltd C0-Crystals
CN104230936A (zh) * 2009-12-03 2014-12-24 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
EP2707367B1 (en) * 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
AU2013204159B2 (en) * 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound

Also Published As

Publication number Publication date
EP2970247A1 (en) 2016-01-20
AU2017201916A1 (en) 2017-04-13
AU2017201916B2 (en) 2018-09-27
CA2905570A1 (en) 2014-09-18
EP2970247A4 (en) 2016-08-10
US10266529B2 (en) 2019-04-23
US20170362230A1 (en) 2017-12-21
AU2014231722A1 (en) 2015-09-24
MX2015013059A (es) 2016-08-05
JP2016510768A (ja) 2016-04-11
WO2014138812A1 (en) 2014-09-18
HK1220191A1 (zh) 2017-04-28
CN105492440A (zh) 2016-04-13
US20160185770A1 (en) 2016-06-30
US9745296B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
AU2014231722B2 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
CA3119656A1 (en) Macrocyclic compounds and their use in the treatment of disease
US20170305905A1 (en) Crystalline form of an anxiolytic compound
EP3402793A1 (en) Pyridazine derivatives as eaat2 activators
EP3617195B1 (en) Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
TW200817402A (en) Substituted pteridines
WO2019014460A1 (en) MOLECULES ENHANCING EAAT2
US11814383B2 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
EP3801528A1 (en) Eaat2 activators and methods of using thereof
US20250333371A1 (en) Compounds
CN107001318A (zh) 可用于治疗与中枢神经系统有关的疾病或病症的n‑(杂)芳基‑取代的杂环衍生物
HK1220187B (en) A crystalline form of an anxiolytic compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)